Pacritinib inhibits glucose consumption in squamous cell lung cancer cells by targeting FLT3
Abstract Squamous cell lung cancer maintains its growth through elevated glucose consumption, but selective glucose consumption inhibitors are lacking. Here, we discovered using a high-throughput screen new compounds that block glucose consumption in three squamous cell lung cancer cell lines and id...
Main Authors: | Chiara Ghezzi, Bao Ying Chen, Robert Damoiseaux, Peter M. Clark |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-01-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-28576-2 |
Similar Items
-
Pacritinib inhibits proliferation of primary effusion lymphoma cells and production of viral interleukin-6 induced cytokines
by: Yiquan Wu, et al.
Published: (2024-02-01) -
Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
by: Srdan Verstovsek, et al.
Published: (2016-12-01) -
Profile of pacritinib and its potential in the treatment of hematologic disorders
by: Hatzimichael E, et al.
Published: (2014-08-01) -
Inhibition of FLT3 expression by green tea catechins in FLT3 mutated-AML cells.
by: Bui Thi Kim Ly, et al.
Published: (2013-01-01) -
P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS
by: A. Vannucchi, et al.
Published: (2022-06-01)